SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

PNV PolyNovo Limited

Healthcare · Medical Devices · website · 301 employees
$0.91
52wk 0.81 – 1.56
Overall
50.6
Value
20.1
Growth
55.2
Health
100.0
Quality
48.0
Momentum
21.8
Dividend
—
Price
About PolyNovo Limited

PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, Hong Kong, and China. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn; NovoSorb MTX for burns, chronic, trauma, and surgical wounds; and hernia repair, plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

Price analytics

Returns

1 day 0.6%
1 week -5.2%
1 month -11.3%
3 months -9.5%
6 months -7.2%
1 year -41.2%
3 years -26.4%

Risk

Volatility (1y ann.) 53.0%
Beta vs ASX 200 1.36
Sharpe (1y) -0.81
VaR 95% (1-day) -5.2%
Max drawdown (1y) -45.1%
Off 1-year high -39.1%

Technicals

RSI(14) 30 OS
vs 50DMA -6.2%
vs 200DMA -10.5%
Trend Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 20.1
Trailing P/E
0
Forward P/E
6
PEG ratio
59
EV / EBITDA
0
Price / Book
15
Price / Sales
63
Growth 55.2
Revenue growth (1y)
66
Revenue CAGR (3y)
100
EPS growth (1y)
0
EPS CAGR (3y)
—
Financial Health 100.0
Net debt / EBITDA
100
Interest coverage (EBIT/interest)
100
Current ratio
100
Debt / Equity
100
Quality (Profitability & Cash Flow) 48.0
Return on equity
42
Return on assets
64
Operating margin
56
Net margin
33
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 21.8
6-month return vs ASX 200
35
Price vs 200-day average
15
Price vs 50-day average
19
Position in 52-week range
13

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$625.21M
P/E (trailing)
90.50
P/E (forward)
33.24
EPS (trailing)
0.01
Dividend yield
—
Payout ratio
0.0%
Beta
1.36
EV / EBITDA
39.28
Price / Book
6.91
ROE
8.4%
Operating margin
14.1%
Net margin
4.9%
Total cash
$35.47M
Total debt
$17.61M
Current ratio
2.99
Debt / Equity
0.19
Free cash flow
$-1.82M
Avg volume
1.96M
Latest annual results (FY ending 30 Jun 2026)
  • Revenue$143.71M
  • Gross profit$128.48M
  • Operating income$10.47M
  • Net income$7.34M
  • Diluted EPS0.01
  • Free cash flow$9.31M
  • Net debt-$17.81M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4